Cellectar Biosciences(US:CLRB)2026-03-04 14:32Financial Data and Key Metrics Changes - The company ended 2025 with cash and cash equivalents of $13.2 million, down from $23.3 million at the end of 2024 [8] - Net loss for the full year 2025 was $21.8 million or $8.35 per share, compared to a net loss of $44.6 million or $36.52 per share in 2024 [10] - Research and development expenses decreased to approximately $11.5 million in Q4 2025 from $26.6 million in 2024, primarily due to the conclusion of patient enrollment in the CLOVER-WaM clinical study [9] Business Line Data and Key Metrics Changes - The company advanced its lead asset, Iopofosine I 131, and initiated a phase 1b study of CLR 125 in triple-negative breast cancer [4][6] - CLR 125 is designed for precise tumor targeting, with early interim data expected in mid-2026 [7] - The company raised approximately $15.2 million throughout 2025 to support ongoing advancements in its pipeline [7] Market Data and Key Metrics Changes - The European market for the second-line setting is estimated to be over 12,000 patients, slightly higher than the U.S. market [53] - The conditional marketing authorization in Europe is expected to target a third-line or later post-BTKI patient population, with plans to shift to a second-line setting upon the confirmatory study [54] Company Strategy and Development Direction - The company aims to submit a conditional marketing authorization application for Iopofosine I 131 in Europe in Q3 2026, with potential approval and commercialization as early as 2027 [4][5] - The focus remains on advancing the regulatory position in both Europe and the U.S. while engaging in partnering conversations to support global program development [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the CLOVER-WaM data set and the unmet medical need for Iopofosine I 131, anticipating a milestone-rich 2026 [11][18] - The company is optimistic about the potential of Iopofosine across multiple oncology indications, supported by promising data from various studies [15][14] Other Important Information - The company expanded its global intellectual property estate with new patents issued across multiple regions, enhancing protection for its assets [7] - The company has strengthened its supply partnerships for isotopes, which are crucial for future clinical development [16] Q&A Session Summary Question: Can the same submission package for EMA be used for FDA? - Management confirmed that while the formats differ, much of the data is similar and can be applied to both submissions [22][23] Question: What is the timeline for submitting to the FDA post-initiation of the confirmatory study? - The company plans to submit the NDA to the FDA about one to two months after initiating the study, expecting a response within 7 to 9 months [27][26] Question: What is the expected progression-free survival (PFS) compared to standard care? - Management indicated that the primary endpoint for the confirmatory study is PFS, with secondary endpoints including major response rates [37][39] Question: What is the interest level among physicians and patients for participation in the trial? - There is high interest from physicians and patients, with many believing the drug fills a significant need in the market [40][41] Question: What are the plans for distribution in Europe? - The company plans to partner with other parties for commercialization in Europe, leveraging a logistical chain that allows for easier distribution of the product [52][53]